

SECOND REGULAR SESSION

HOUSE BILL NO. 1051

97TH GENERAL ASSEMBLY

INTRODUCED BY REPRESENTATIVE RHOADS.

4111L.011

D. ADAM CRUMBLISS, Chief Clerk

AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to synthetic cannabinoids, with penalty provisions.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Section 195.017, RSMo, is repealed and one new section enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a substance in Schedule I if it finds that the substance:

- (1) Has high potential for abuse; and
- (2) Has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.

2. Schedule I:

- (1) The controlled substances listed in this subsection are included in Schedule I;
- (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

- (a) Acetyl-alpha-methylfentanyl;
- (b) Acetylmethadol;
- (c) Allylprodine;
- (d) Alphacetylmethadol;
- (e) Alphameprodine;
- (f) Alphamethadol;
- (g) Alpha-methylfentanyl;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

- 18 (h) Alpha-methylthiofentanyl;
- 19 (i) Benzethidine;
- 20 (j) Betacetylmethadol;
- 21 (k) Beta-hydroxyfentanyl;
- 22 (l) Beta-hydroxy-3-methylfentanyl;
- 23 (m) Betameprodine;
- 24 (n) Betamethadol;
- 25 (o) Betaprodine;
- 26 (p) Clonitazene;
- 27 (q) Dextromoramide;
- 28 (r) Diampromide;
- 29 (s) Diethylthiambutene;
- 30 (t) Difenoxin;
- 31 (u) Dimenoxadol;
- 32 (v) Dimepheptanol;
- 33 (w) Dimethylthiambutene;
- 34 (x) Dioxaphetyl butyrate;
- 35 (y) Dipipanone;
- 36 (z) Ethylmethylthiambutene;
- 37 (aa) Etonitazene;
- 38 (bb) Etoxidine;
- 39 (cc) Furethidine;
- 40 (dd) Hydroxypethidine;
- 41 (ee) Ketobemidone;
- 42 (ff) Levomoramide;
- 43 (gg) Levophenacymorphan;
- 44 (hh) 3-Methylfentanyl;
- 45 (ii) 3-Methylthiofentanyl;
- 46 (jj) Morpheridine;
- 47 (kk) MPPP;
- 48 (ll) Noracymethadol;
- 49 (mm) Norlevorphanol;
- 50 (nn) Normethadone;
- 51 (oo) Norpipanone;
- 52 (pp) Para-fluorofentanyl;
- 53 (qq) PEPAP;

- 54 (rr) Phenadoxone;
- 55 (ss) Phenampromide;
- 56 (tt) Phenomorphan;
- 57 (uu) Phenoperidine;
- 58 (vv) Piritramide;
- 59 (ww) Proheptazine;
- 60 (xx) Properidine;
- 61 (yy) Propiram;
- 62 (zz) Racemoramide;
- 63 (aaa) Thiofentanyl;
- 64 (bbb) Tilidine;
- 65 (ccc) Trimeperidine;

66 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers
67 unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers
68 is possible within the specific chemical designation:

- 69 (a) Acetorphine;
- 70 (b) Acetyldihydrocodeine;
- 71 (c) Benzylmorphine;
- 72 (d) Codeine methylbromide;
- 73 (e) Codeine-N-Oxide;
- 74 (f) Cyprenorphine;
- 75 (g) Desomorphine;
- 76 (h) Dihydromorphine;
- 77 (i) Drotebanol;
- 78 (j) Etorphine (except hydrochloride salt);
- 79 (k) Heroin;
- 80 (l) Hydromorphinol;
- 81 (m) Methyldesorphine;
- 82 (n) Methyldihydromorphine;
- 83 (o) Morphine methylbromide;
- 84 (p) Morphine methylsulfonate;
- 85 (q) Morphine-N-Oxide;
- 86 (r) Myrophine;
- 87 (s) Nicocodeine;
- 88 (t) Nicomorphine;
- 89 (u) Normorphine;

- 90 (v) Pholcodine;
- 91 (w) Thebacon;
- 92 (4) Any material, compound, mixture or preparation which contains any quantity of the
- 93 following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically
- 94 excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within
- 95 the specific chemical designation:
- 96 (a) 4-bromo-2, 5-dimethoxyamphetamine;
- 97 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
- 98 (c) 2,5-dimethoxyamphetamine;
- 99 (d) 2,5-dimethoxy-4-ethylamphetamine;
- 100 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 101 (f) 4-methoxyamphetamine;
- 102 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
- 103 (h) 4-methyl-2, 5-dimethoxyamphetamine;
- 104 (i) 3,4-methylenedioxyamphetamine;
- 105 (j) 3,4-methylenedioxymethamphetamine;
- 106 (k) 3,4-methylenedioxy-N-ethylamphetamine;
- 107 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
- 108 (m) 3,4,5-trimethoxyamphetamine;
- 109 (n) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine, its isomers, salts, and salts of
- 110 isomers;
- 111 (o) Alpha-ethyltryptamine;
- 112 (p) Alpha-methyltryptamine;
- 113 (q) Bufotenine;
- 114 (r) Diethyltryptamine;
- 115 (s) Dimethyltryptamine;
- 116 (t) 5-methoxy-N,N-diisopropyltryptamine;
- 117 (u) Ibogaine;
- 118 (v) Lysergic acid diethylamide;
- 119 (w) Marijuana or marihuana;
- 120 (x) Mescaline;
- 121 (y) Parahexyl;
- 122 (z) Peyote, to include all parts of the plant presently classified botanically as Lophophora
- 123 Williamsil Lemaire, whether growing or not; the seeds thereof; any extract from any part of such
- 124 plant; and every compound, manufacture, salt, derivative, mixture or preparation of the plant,
- 125 its seed or extracts;

- 126 (aa) N-ethyl-3-piperidyl benzilate;
127 (bb) N-methyl-3-piperidyl benzilate;
128 (cc) Psilocybin;
129 (dd) Psilocyn;
130 (ee) Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis
131 (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis
132 plant, or in the resinous extractives of such plant, or synthetic substances, derivatives, and their
133 isomers with similar chemical structure and pharmacological activity to those substances
134 contained in the plant, such as the following:
- 135 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;
 - 136 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;
 - 137 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;
 - 138 d. Any compounds of these structures, regardless of numerical designation of atomic
139 positions covered;
 - 140 (ff) Ethylamine analog of phencyclidine;
 - 141 (gg) Pyrrolidine analog of phencyclidine;
 - 142 (hh) Thiophene analog of phencyclidine;
 - 143 (ii) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
 - 144 (jj) Salvia divinorum;
 - 145 (kk) Salvinorin A;
 - 146 (ll) Synthetic cannabinoids:
 - 147 a. Any compound structurally derived from 3-(1-naphthoyl)indole or
148 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by
149 alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl
150 [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-pyrrolidiny)methyl, 1-(N-methyl-3-**
151 **morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl** group, whether or not further
152 substituted in the indole ring to any extent, whether or not substituted in the naphthyl ring to any
153 extent. Including, but not limited to:
 - 154 (i) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;
 - 155 (ii) JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole;
 - 156 (iii) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;
 - 157 (iv) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;
 - 158 (v) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;
 - 159 (vi) JWH-081, or 1-pentyl-3-(4-methoxy-1-naphthoyl)indole;
 - 160 (vii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;
 - 161 (viii) JWH-122, or 1-pentyl-3-(4-methyl-1-naphthoyl)indole;

- 162 (ix) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
163 (x) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
164 (xi) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole;
165 (xii) JWH-398, or 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
- 166 b. Any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the
167 nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
168 1-(N-methyl-2-piperidiny)methyl [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-pyrrolidinyl)**
169 **methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl** group, whether
170 or not further substituted in the pyrrole ring to any extent, whether or not substituted in the
171 naphthyl ring to any extent;
- 172 c. Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution
173 at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
174 cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-**
175 **pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl**
176 group, whether or not further substituted in the indene ring to any extent, whether or not
177 substituted in the naphthyl ring to any extent;
- 178 d. Any compound structurally derived from 3-phenylacetylindole by substitution at the
179 nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
180 1-(N-methyl-2-piperidiny)methyl [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-**
181 **pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl**
182 group, whether or not further substituted in the indole ring to any extent, whether or not
183 substituted in the phenyl ring to any extent. Including, but not limited to:
- 184 (i) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole;
185 (ii) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole;
186 (iii) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole;
187 (iv) JWH-251, or 1-pentyl-3-(2-methylphenylacetyl)indole;
188 (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole;
- 189 e. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by
190 substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
191 cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-**
192 **pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl**
193 group, whether or not substituted in the cyclohexyl ring to any extent. Including, but not limited
194 to:
- 195 (i) C P 47, 497 & homologues, or 2-[(1R,3S)-3-
196 hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol), where side chain n=5, and homologues
197 where side chain n=4,6, or 7;

f. Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl** group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Including, but not limited to:

(i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;

(ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole;

g. Any compound structurally derived from **1H-indol-3-yl-(2,2,3,3-tetramethylcyclopropyl)-methanone** by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent. Including, but not limited to:

(i) UR-144, or (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone;

(ii) **XLR-11, or (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;**

h. Any compound structurally derived from **3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole** by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent, whether or not substituted in the adamantyl group to any extent. Including, but not limited to:

(i) AM-1248, or 1-(N-methyl-2-piperidinyl)methyl-3-(1-adamantoyl)indole;

(ii) AB-001, or 1-pentyl-3-(1-adamantoyl)indole;

i. Any compound structurally derived from **N-adamantyl-1H-indole-3-carboxamide** by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent, whether or not substituted in the adamantyl group to any extent. Including, but not limited to **2NE1, or 1-pentyl-N-adamantyl-1H-indole-3-carboxamide;**

j. Any compound structurally derived from the **N-adamantyl-1H-indazole-3-carboxamide** by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-

morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent, whether or not substituted in the adamantyl group to any extent. Including, but not limited to AKB48, or 1-pentyl-N-adamantyl-1H-indazole-3-carboxamide;

k. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;

[h.] l. HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

[i.] m. HU-211, or Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

[j.] CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;

k.] n. Dimethylheptylpyran, or DMHP;

(5) Any material, compound, mixture or preparation containing any quantity of the following substances having a depressant effect on the central nervous system, including their salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

(a) Gamma-hydroxybutyric acid;

(b) Mecloqualone;

(c) Methaqualone;

(6) Any material, compound, mixture or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers and salts of isomers:

(a) Aminorex;

(b) N-benzylpiperazine;

(c) Cathinone;

(d) Fenethylamine;

(e) 3-Fluoromethcathinone;

(f) 4-Fluoromethcathinone;

(g) Mephedrone, or 4-methylmethcathinone;

(h) Methcathinone;

(i) 4-methoxymethcathinone;

(j) (+,-)-cis-4-methylaminorex ((+,-)-cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazoline);

(k) Methylenedioxypyrovalerone, MDPV, or (1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone;

(l) Methylone, or 3,4-Methylenedioxymethcathinone;

(m) 4-Methyl-alpha-pyrrolidinobutylphenone, or MPBP;

270 (n) N-ethylamphetamine;
271 (o) N,N-dimethylamphetamine;
272 (7) A temporary listing of substances subject to emergency scheduling under federal law
273 shall include any material, compound, mixture or preparation which contains any quantity of the
274 following substances:
275 (a) N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), its optical isomers,
276 salts and salts of isomers;
277 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its
278 optical isomers, salts and salts of isomers;
279 (8) Khat, to include all parts of the plant presently classified botanically as catha edulis,
280 whether growing or not; the seeds thereof; any extract from any part of such plant; and every
281 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.
282 3. The department of health and senior services shall place a substance in Schedule II
283 if it finds that:
284 (1) The substance has high potential for abuse;
285 (2) The substance has currently accepted medical use in treatment in the United States,
286 or currently accepted medical use with severe restrictions; and
287 (3) The abuse of the substance may lead to severe psychic or physical dependence.
288 4. The controlled substances listed in this subsection are included in Schedule II:
289 (1) Any of the following substances whether produced directly or indirectly by extraction
290 from substances of vegetable origin, or independently by means of chemical synthesis, or by
291 combination of extraction and chemical synthesis:
292 (a) Opium and opiate and any salt, compound, derivative or preparation of opium or
293 opiate, excluding apomorphine, thebaine-derived butorphanol, dextrophan, nalbuphine,
294 nalmeferene, naloxone and naltrexone, and their respective salts but including the following:
295 a. Raw opium;
296 b. Opium extracts;
297 c. Opium fluid;
298 d. Powdered opium;
299 e. Granulated opium;
300 f. Tincture of opium;
301 g. Codeine;
302 h. Ethylmorphine;
303 i. Etorphine hydrochloride;
304 j. Hydrocodone;
305 k. Hydromorphone;

- 306 l. Metopon;
- 307 m. Morphine;
- 308 n. Oxycodone;
- 309 o. Oxymorphone;
- 310 p. Thebaine;
- 311 (b) Any salt, compound, derivative, or preparation thereof which is chemically
- 312 equivalent or identical with any of the substances referred to in this subdivision, but not
- 313 including the isoquinoline alkaloids of opium;
- 314 (c) Opium poppy and poppy straw;
- 315 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
- 316 any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical
- 317 with any of these substances, but not including decocainized coca leaves or extractions which
- 318 do not contain cocaine or ecgonine;
- 319 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid
- 320 or powder form which contains the phenanthrene alkaloids of the opium poppy);
- 321 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
- 322 of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within
- 323 the specific chemical designation, dextrophan and levopropoxyphene excepted:
- 324 (a) Alfentanil;
- 325 (b) Alphaprodine;
- 326 (c) Anileridine;
- 327 (d) Bezitramide;
- 328 (e) Bulk dextropropoxyphene;
- 329 (f) Carfentanil;
- 330 (g) Dihydrocodeine;
- 331 (h) Diphenoxylate;
- 332 (i) Fentanyl;
- 333 (j) Isomethadone;
- 334 (k) Levo-alphacetylmethadol;
- 335 (l) Levomethorphan;
- 336 (m) Levorphanol;
- 337 (n) Metazocine;
- 338 (o) Methadone;
- 339 (p) Meperidine;
- 340 (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;

- 341 (r) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--carboxylic
342 acid;
- 343 (s) Pethidine (meperidine);
- 344 (t) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 345 (u) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 346 (v) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 347 (w) Phenazocine;
- 348 (x) Piminodine;
- 349 (y) Racemethorphan;
- 350 (z) Racemorphan;
- 351 (aa) Remifentanil;
- 352 (bb) Sufentanil;
- 353 (cc) Tapentadol;
- 354 (3) Any material, compound, mixture, or preparation which contains any quantity of the
355 following substances having a stimulant effect on the central nervous system:
- 356 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 357 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
- 358 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
- 359 (d) Phenmetrazine and its salts;
- 360 (e) Methylphenidate;
- 361 (4) Any material, compound, mixture, or preparation which contains any quantity of the
362 following substances having a depressant effect on the central nervous system, including its salts,
363 isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers
364 is possible within the specific chemical designation:
- 365 (a) Amobarbital;
- 366 (b) Glutethimide;
- 367 (c) Pentobarbital;
- 368 (d) Phencyclidine;
- 369 (e) Secobarbital;
- 370 (5) Any material or compound which contains any quantity of nabilone;
- 371 (6) Any material, compound, mixture, or preparation which contains any quantity of the
372 following substances:
- 373 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;
- 374 (b) Immediate precursors to phencyclidine (PCP):
- 375 a. 1-phenylcyclohexylamine;
- 376 b. 1-piperidinocyclohexanecarbonitrile (PCC);

377 (7) Any material, compound, mixture, or preparation which contains any quantity of the
378 following alkyl nitrites:

379 (a) Amyl nitrite;

380 (b) Butyl nitrite.

381 5. The department of health and senior services shall place a substance in Schedule III
382 if it finds that:

383 (1) The substance has a potential for abuse less than the substances listed in Schedules
384 I and II;

385 (2) The substance has currently accepted medical use in treatment in the United States;
386 and

387 (3) Abuse of the substance may lead to moderate or low physical dependence or high
388 psychological dependence.

389 6. The controlled substances listed in this subsection are included in Schedule III:

390 (1) Any material, compound, mixture, or preparation which contains any quantity of the
391 following substances having a potential for abuse associated with a stimulant effect on the
392 central nervous system:

393 (a) Benzphetamine;

394 (b) Chlorphentermine;

395 (c) Clortermine;

396 (d) Phendimetrazine;

397 (2) Any material, compound, mixture or preparation which contains any quantity or salt
398 of the following substances or salts having a depressant effect on the central nervous system:

399 (a) Any material, compound, mixture or preparation which contains any quantity or salt
400 of the following substances combined with one or more active medicinal ingredients:

401 a. Amobarbital;

402 b. Secobarbital;

403 c. Pentobarbital;

404 (b) Any suppository dosage form containing any quantity or salt of the following:

405 a. Amobarbital;

406 b. Secobarbital;

407 c. Pentobarbital;

408 (c) Any substance which contains any quantity of a derivative of barbituric acid or its
409 salt;

410 (d) Chlorhexadol;

411 (e) Embutramide;

- 412 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in
413 a drug product for which an application has been approved under Section 505 of the federal
414 Food, Drug, and Cosmetic Act;
- 415 (g) Ketamine, its salts, isomers, and salts of isomers;
- 416 (h) Lysergic acid;
- 417 (i) Lysergic acid amide;
- 418 (j) Methyprylon;
- 419 (k) Sulfondiethylmethane;
- 420 (l) Sulfonethylmethane;
- 421 (m) Sulfonmethane;
- 422 (n) Tiletamine and zolazepam or any salt thereof;
- 423 (3) Nalorphine;
- 424 (4) Any material, compound, mixture, or preparation containing limited quantities of any
425 of the following narcotic drugs or their salts:
- 426 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
427 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
428 of opium;
- 429 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
430 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized
431 therapeutic amounts;
- 432 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
433 or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an
434 isoquinoline alkaloid of opium;
- 435 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
436 or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic
437 ingredients in recognized therapeutic amounts;
- 438 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not more
439 than ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in
440 recognized therapeutic amounts;
- 441 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters
442 or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic
443 ingredients in recognized therapeutic amounts;
- 444 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per
445 one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more
446 active nonnarcotic ingredients in recognized therapeutic amounts;

(h) Not more than fifty milligrams of morphine per one hundred milliliters or per one hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(5) Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts, as set forth in subdivision (6) of this subsection; buprenorphine;

(6) Anabolic steroids. Any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the Secretary of Health and Human Services for that administration. If any person prescribes, dispenses, or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this subdivision. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any quantity of the following substances, including its salts, esters and ethers:

- (a) 3 β ,17-dihydroxy-5 α -androstane;
- (b) 3 α ,17 β -dihydroxy-5 α -androstane;
- (c) 5 α -androstan-3,17-dione;
- (d) 1-androstenediol (3 β ,17 β -dihydroxy-5 α -androst-1-ene);
- (e) 1-androstenediol (3 α ,17 β -dihydroxy-5 α -androst-1-ene);
- (f) 4-androstenediol (3 β ,17 β -dihydroxy-androst-4-ene);
- (g) 5-androstenediol (3 β ,17 β -dihydroxy-androst-5-ene);
- (h) 1-androstenedione ([5 α]-androst-1-en-3,17-dione);
- (i) 4-androstenedione (androst-4-en-3,17-dione);
- (j) 5-androstenedione (androst-5-en-3,17-dione);
- (k) Bolasterone (7 α , 17 α -dimethyl-17 β -hydroxyandrost-4-en-3-one);
- (l) Boldenone (17 β -hydroxyandrost-1,4,-diene-3-one);
- (m) Boldione;
- (n) Calusterone (7 β , 17 α -dimethyl-17 β -hydroxyandrost-4-en-3-one);
- (o) Clostebol (4-chloro-17 β -hydroxyandrost-4-en-3-one);
- (p) Dehydrochloromethyltestosterone (4-chloro-17 β -hydroxy-17 α -methyl-androst-1,4-dien-3-one);
- (q) Desoxymethyltestosterone;
- (r) Δ 1-dihydrotestosterone (a.k.a. '1-testosterone')(17 β -hydroxy-5 α -androst-1-en-3-one);
- (s) 4-dihydrotestosterone (17 β -hydroxy-androstan-3-one);
- (t) Drostanolone (17 β -hydroxy-2 α -methyl-5 α -androstan-3-one);

- 483 (u) Ethylestrenol (17 α -ethyl-17 β -hydroxyestr-4-ene);
484 (v) Fluoxymesterone (9-fluoro-17 α -methyl-11 β ,17 β -dihydroxyandrost-4-en-3-one);
485 (w) Formebolone (2-formyl-17 α -methyl-11 α ,17 β -dihydroxyandrost-1,4-dien-3-one);
486 (x) Furazabol (17 α -methyl-17 β -hydroxyandrostano[2,3-c]-furan);
487 (y) 13 β -ethyl-17 β -hydroxygon-4-en-3-one;
488 (z) 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-one);
489 (aa) 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-en-3-one);
490 (bb) Mestanolone (17 α -methyl-17 β -hydroxy-5-androstan-3-one);
491 (cc) Mesterolone (1 α -methyl-17 β -hydroxy-[5 α]-androstan-3-one);
492 (dd) Methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-dien-3-one);
493 (ee) Methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-ene);
494 (ff) Methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-one);
495 (gg) 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstane);
496 (hh) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstane);
497 (ii) 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene;
498 (jj) 17 α -methyl-4-hydroxynandrolone (17 α -methyl-4-hydroxy-17 β -
499 hydroxyestr-4-en-3-one);
500 (kk) Methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-dien-3-one);
501 (ll) Methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9-11-trien-3-one);
502 (mm) Methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-en-3-one);
503 (nn) Mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-one);
504 (oo) 17 α -methyl- Δ 1-dihydrotestosterone (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-
505 one) (a.k.a. '17- α -methyl-1-testosterone');
506 (pp) Nandrolone (17 β -hydroxyestr-4-ene-3-one);
507 (qq) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
508 (rr) 19-nor-4-androstenediol (3 α ,17 β -dihydroxyestr-4-ene);
509 (ss) 19-nor-4,9(10)-androstadienedione;
510 (tt) 19-nor-5-androstenediol (3 β ,17 β -dihydroxyestr-5-ene);
511 (uu) 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene);
512 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
513 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
514 (xx) Norbolethone (13 β ,17 α -diethyl-17 β -hydroxygon-4-en-3-one);
515 (yy) Norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
516 (zz) Norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-one);
517 (aaa) Normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-one);
518 (bbb) Oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-androstan-3-one);

519 (ccc) Oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-en-3-one);
520 (ddd) Oxymethalone (17 α -methyl-2-hydroxymethylene-17 β -hydroxy-[5 α]-
521 androstan-3-one);
522 (eee) Stanozolol (17 α -methyl-17 β -hydroxy-[5 α]-androst-2-eno[3,2-c]-pyrazole);
523 (fff) Stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-one);
524 (ggg) Testolactone (13-hydroxy-3-oxo-13,17-secoandrost-1,4-dien-17-oic acid lactone);
525 (hhh) Testosterone (17 β -hydroxyandrost-4-en-3-one);
526 (iii) Tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-4,9,11-trien-3-one);
527 (jjj) Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one);
528 (kkk) Any salt, ester, or ether of a drug or substance described or listed in this
529 subdivision, except an anabolic steroid which is expressly intended for administration through
530 implants to cattle or other nonhuman species and which has been approved by the Secretary of
531 Health and Human Services for that administration;
532 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
533 United States Food and Drug Administration approved drug product;
534 (8) The department of health and senior services may except by rule any compound,
535 mixture, or preparation containing any stimulant or depressant substance listed in subdivisions
536 (1) and (2) of this subsection from the application of all or any part of sections 195.010 to
537 195.320 if the compound, mixture, or preparation contains one or more active medicinal
538 ingredients not having a stimulant or depressant effect on the central nervous system, and if the
539 admixtures are included therein in combinations, quantity, proportion, or concentration that
540 vitiate the potential for abuse of the substances which have a stimulant or depressant effect on
541 the central nervous system.
542 7. The department of health and senior services shall place a substance in Schedule IV
543 if it finds that:
544 (1) The substance has a low potential for abuse relative to substances in Schedule III;
545 (2) The substance has currently accepted medical use in treatment in the United States;
546 and
547 (3) Abuse of the substance may lead to limited physical dependence or psychological
548 dependence relative to the substances in Schedule III.
549 8. The controlled substances listed in this subsection are included in Schedule IV:
550 (1) Any material, compound, mixture, or preparation containing any of the following
551 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
552 as set forth below:
553 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms
554 of atropine sulfate per dosage unit;

555 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-
556 propionoxybutane);

557 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall
558 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer
559 upon the compound, mixture or preparation valuable medicinal qualities other than those
560 possessed by the narcotic drug alone:

561 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per
562 one hundred grams;

563 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters
564 or per one hundred grams;

565 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters
566 or per one hundred grams;

567 (2) Any material, compound, mixture or preparation containing any quantity of the
568 following substances, including their salts, isomers, and salts of isomers whenever the existence
569 of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

570 (a) Alprazolam;

571 (b) Barbitol;

572 (c) Bromazepam;

573 (d) Camazepam;

574 (e) Chloral betaine;

575 (f) Chloral hydrate;

576 (g) Chlordiazepoxide;

577 (h) Clobazam;

578 (i) Clonazepam;

579 (j) Clorazepate;

580 (k) Clotiazepam;

581 (l) Cloxazolam;

582 (m) Delorazepam;

583 (n) Diazepam;

584 (o) Dichloralphenazone;

585 (p) Estazolam;

586 (q) Ethchlorvynol;

587 (r) Ethinamate;

588 (s) Ethyl loflazepate;

589 (t) Fludiazepam;

590 (u) Flunitrazepam;

591 (v) Flurazepam;
592 (w) Fospropofol;
593 (x) Halazepam;
594 (y) Haloxazolam;
595 (z) Ketazolam;
596 (aa) Loprazolam;
597 (bb) Lorazepam;
598 (cc) Lormetazepam;
599 (dd) Mebutamate;
600 (ee) Medazepam;
601 (ff) Meprobamate;
602 (gg) Methohexital;
603 (hh) Methylphenobarbital (mephobarbital);
604 (ii) Midazolam;
605 (jj) Nimetazepam;
606 (kk) Nitrazepam;
607 (ll) Nordiazepam;
608 (mm) Oxazepam;
609 (nn) Oxazolam;
610 (oo) Paraldehyde;
611 (pp) Petrichloral;
612 (qq) Phenobarbital;
613 (rr) Pinazepam;
614 (ss) Prazepam;
615 (tt) Quazepam;
616 (uu) Temazepam;
617 (vv) Tetrazepam;
618 (ww) Triazolam;
619 (xx) Zaleplon;
620 (yy) Zolpidem;
621 (zz) Zopiclone;
622 (3) Any material, compound, mixture, or preparation which contains any quantity of the
623 following substance including its salts, isomers and salts of isomers whenever the existence of
624 such salts, isomers and salts of isomers is possible: fenfluramine;

625 (4) Any material, compound, mixture or preparation containing any quantity of the
626 following substances having a stimulant effect on the central nervous system, including their
627 salts, isomers and salts of isomers:

- 628 (a) Cathine ((+)-norpseudoephedrine);
- 629 (b) Diethylpropion;
- 630 (c) Fencamfamin;
- 631 (d) Fenproporex;
- 632 (e) Mazindol;
- 633 (f) Mefenorex;
- 634 (g) Modafinil;
- 635 (h) Pemoline, including organometallic complexes and chelates thereof;
- 636 (i) Phentermine;
- 637 (j) Pipradrol;
- 638 (k) Sibutramine;
- 639 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);

640 (5) Any material, compound, mixture or preparation containing any quantity of the
641 following substance, including its salts:

- 642 (a) butorphanol;
- 643 (b) pentazocine;

644 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance
645 is the only active medicinal ingredient;

646 (7) The department of health and senior services may except by rule any compound,
647 mixture, or preparation containing any depressant substance listed in subdivision (1) of this
648 subsection from the application of all or any part of sections 195.010 to 195.320 if the
649 compound, mixture, or preparation contains one or more active medicinal ingredients not having
650 a depressant effect on the central nervous system, and if the admixtures are included therein in
651 combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the
652 substances which have a depressant effect on the central nervous system.

653 9. The department of health and senior services shall place a substance in Schedule V
654 if it finds that:

655 (1) The substance has low potential for abuse relative to the controlled substances listed
656 in Schedule IV;

657 (2) The substance has currently accepted medical use in treatment in the United States;
658 and

659 (3) The substance has limited physical dependence or psychological dependence liability
660 relative to the controlled substances listed in Schedule IV.

661 10. The controlled substances listed in this subsection are included in Schedule V:

662 (1) Any compound, mixture or preparation containing any of the following narcotic
663 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set
664 forth below, which also contains one or more nonnarcotic active medicinal ingredients in
665 sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal
666 qualities other than those possessed by the narcotic drug alone:

667 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than
668 twenty-five micrograms of atropine sulfate per dosage unit;

669 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per
670 one hundred grams;

671 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five
672 micrograms of atropine sulfate per dosage unit;

673 (2) Any material, compound, mixture or preparation which contains any quantity of the
674 following substance having a stimulant effect on the central nervous system including its salts,
675 isomers and salts of isomers: pyrovalerone;

676 (3) Any compound, mixture, or preparation containing any detectable quantity of
677 pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound,
678 mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical
679 isomers, or salts of optical isomers;

680 (4) Unless specifically exempted or excluded or unless listed in another schedule, any
681 material, compound, mixture, or preparation which contains any quantity of the following
682 substances having a depressant effect on the central nervous system, including its salts:

683 (a) Lacosamide;

684 (b) Pregabalin.

685 11. If any compound, mixture, or preparation as specified in subdivision (3) of
686 subsection 10 of this section is dispensed, sold, or distributed in a pharmacy without a
687 prescription:

688 (1) All packages of any compound, mixture, or preparation containing any detectable
689 quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine,
690 its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind
691 a pharmacy counter where the public is not permitted, and only by a registered pharmacist or
692 registered pharmacy technician; and

693 (2) Any person purchasing, receiving or otherwise acquiring any compound, mixture,
694 or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers,
695 or salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers
696 shall be at least eighteen years of age; and

697 (3) The pharmacist, intern pharmacist, or registered pharmacy technician shall require
698 any person, [prior to their] **before such person's** purchasing, receiving or otherwise acquiring
699 such compound, mixture, or preparation to furnish suitable photo identification that is issued by
700 a state or the federal government or a document that, with respect to identification, is considered
701 acceptable and showing the date of birth of the person;

702 (4) The seller shall deliver the product directly into the custody of the purchaser.

703 12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall
704 implement and maintain an electronic log of each transaction. Such log shall include the
705 following information:

706 (1) The name, address, and signature of the purchaser;

707 (2) The amount of the compound, mixture, or preparation purchased;

708 (3) The date and time of each purchase; and

709 (4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy
710 technician who dispensed the compound, mixture, or preparation to the purchaser.

711 13. Each pharmacy shall submit information regarding sales of any compound, mixture,
712 or preparation as specified in subdivision (3) of subsection 10 of this section in accordance with
713 transmission methods and frequency established by the department by regulation;

714 14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities
715 greater than those specified in this chapter.

716 15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products
717 in a pharmacy shall ensure that all such products are located only behind a pharmacy counter
718 where the public is not permitted.

719 16. Any person who knowingly or recklessly violates the provisions of subsections 11
720 to 15 of this section is guilty of a class A misdemeanor.

721 17. The scheduling of substances specified in subdivision (3) of subsection 10 of this
722 section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds,
723 mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound,
724 mixture, or preparation specified in subdivision (3) of subsection 10 of this section which must
725 be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.

726 18. The manufacturer of a drug product or another interested party may apply with the
727 department of health and senior services for an exemption from this section. The department of
728 health and senior services may grant an exemption by rule from this section if the department
729 finds the drug product is not used in the illegal manufacture of methamphetamine or other
730 controlled or dangerous substances. The department of health and senior services shall rely on
731 reports from law enforcement and law enforcement evidentiary laboratories in determining if the
732 proposed product can be used to manufacture illicit controlled substances.

733 19. The department of health and senior services shall revise and republish the schedules
734 annually.

735 20. The department of health and senior services shall promulgate rules under chapter
736 536 regarding the security and storage of Schedule V controlled substances, as described in
737 subdivision (3) of subsection 10 of this section, for distributors as registered by the department
738 of health and senior services.

739 21. Logs of transactions required to be kept and maintained by this section and section
740 195.417 shall create a rebuttable presumption that the person whose name appears in the logs is
741 the person whose transactions are recorded in the logs.

✓